Volume 137: Hydrochlorothiazide, voriconazole, and tacrolimus

We are pleased to announce that the results of the recent IARC Monographs evaluation of the carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus have now been published in The Lancet Oncology. This summary article presents the conclusions of IARC Monographs Meeting 137.

Hydrochlorothiazide and other phototoxic drugs were accorded high priority by the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024. Hydrochlorothiazide was previously evaluated by the IARC Monographs in Volumes 50 and 108. Voriconazole and tacrolimus were evaluated for the first time.

Hydrochlorothiazide is the most common prescription-only oral thiazide diuretic drug used worldwide to treat essential hypertension and peripheral oedema. Although partly replaced by other antihypertensives, hydrochlorothiazide remains a commonly prescribed drug because of the high prevalence of hypertension. It is frequently used in a single pill combination that also contains angiotensin receptor blockers. Interaction of the hydrochlorothiazide molecule with ultraviolet radiation leads to phototoxicity.

Voriconazole is a broad-spectrum triazole drug used as curative treatment or prophylaxis for invasive aspergillosis and other serious fungal infections, which are especially common in transplant recipients. It is approved in most countries worldwide for use in adults and children (age > 2 years). The metabolite, voriconazole N-oxide, is phototoxic.

Tacrolimus is a calcineurin inhibitor used in oral and intravenous formulations as an immunosuppressive medication to reduce the risk of rejection of solid organ transplants in adults and children, and to prevent graft-versus-host disease. Topical tacrolimus is a second-line therapy for the treatment of atopic dermatitis and vitiligo. Information regarding the phototoxicity of tacrolimus is scarce.

Hydrochlorothiazide, voriconazole, and tacrolimus are all listed in the World Health Organization Model List of Essential Medicines. The main exposures to hydrochlorothiazide, voriconazole, and tacrolimus are from medications.

The Working Group evaluated hydrochlorothiazide, voriconazole, and tacrolimus as carcinogenic to humans (Group 1) on the basis of sufficient evidence for cancer in humans for each agent. For tacrolimus, a Group 1 evaluation was also reached on the basis of sufficient evidence for cancer in experimental animals and strong mechanistic evidence in exposed humans.

There was sufficient evidence that hydrochlorothiazide causes squamous cell carcinoma of skin and cancer of the lip in humans. The evidence was limited for a causal association between hydrochlorothiazide and basal cell carcinoma of skin, melanoma of the skin, Merkel cell carcinoma, and malignant adnexal skin tumours. There was also sufficient evidence for cancer in experimental animals and limited mechanistic evidence.

There was sufficient evidence that voriconazole causes squamous cell carcinoma of skin in humans. There was also strong mechanistic evidence in exposed humans (for alteration of cell proliferation, cell death, or nutrient supply) and human primary cells (for oxidative stress).

There was sufficient evidence that tacrolimus causes non-Hodgkin lymphoma and post-transplant lymphoproliferative disorder. The evidence was limited for a causal association between tacrolimus and leukaemia and squamous cell carcinoma of the skin in humans. There was also sufficient evidence for cancer in experimental animals, and strong mechanistic evidence in exposed humans and human primary cells (for immunosuppression), and experimental systems (for genotoxicity, oxidative stress, and immunosuppression).

The full scientific assessment will be published as Volume 137 of the IARC Monographs.

Cogliano V, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, et al.

Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus

Lancet Oncol, Published online 29 November 2024;

https://doi.org/10.1016/S1470-2045(24)00685-5

Read the article

Read the Q&A

View the infographic